# US 2019/0169287 A1 · Treatment of cancer with anti-il-1 alpha antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169287 A1
- Document ID: US20190169287A1
- Status: Published application
- Kind: A1
- Application number: 16/271,235
- Filed: 2019-02-08
- Published: 2019-06-06
- Earliest claimed: 2006-05-22
- Assignees: Xbiotech, Inc.
- Applicants: XBiotech, Inc.
- Inventors: John Simard
- Web page: https://patentgrep.com/patent/US20190169287A1

## CPC

- C07K 16/245: {IL-1}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07K 16/3015: {Breast}
- C07K 16/3061: {Blood cells}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Treating a patient with anti-IL-1α antibody or anti-IL-1α immunization s a cancer treatment.

## Claims

### Claim 1

A method of reducing the formation of new metastases comprising human cancer cells in a subject harboring said human cancer cells, the method comprising a step of administering to the subject an amount of anti-human interleukin-1alpha (IL-1α) antibodies effective to reduce the development of new metastases in the subject, wherein the formation of new metastases in the lungs or liver of the subject is reduced.

### Claim 2 (depends on 1)

The method of claim 1, wherein the new metastases comprise breast or prostate cancer cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibodies are polyclonal.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibodies are monoclonal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the step of administering to the subject an amount of anti-human IL-1α antibodies effective to reduce the development of new metastases in the subject reduces the development of ascites in the subject.